Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IMRT (Intensity modulated radiation therapy) promises more accurate Hodgkin's therapy:

This article was originally published in Clinica

Executive Summary

Intensity modulated radiation therapy (IMRT) can improve the treatment of Hodgkin's disease by enabling a more precise delivery of radiation therapy to tumours while reducing exposure to surrounding healthy tissue, according to a US study. The technique conforms radiation energy to the size, shape and location of a tumour, avoiding drawbacks associated with conventional radiation therapies, which can cause damage to the heart, lung and thyroid and increase the risk of breast and lung cancer, says researcher Dr Billy Loo, of Stanford University, California. The findings were presented last week at the American Society for Therapeutic Radiology and Oncology's annual meeting, in New Orleans.

You may also be interested in...



Can Synthetic CBD Overcome Cannabis Stigma And Break EU Novel Foods Deadlock?

Czech firm CBDepot has filed a novel food application for synthetically made CBD in Europe, which it hopes regulators will find more palatable than those for supplements derived from the cannabis plant.

Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.

Polpharma Pursues Tysabri Through Antelope Trial

The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.

Topics

UsernamePublicRestriction

Register

MT068519

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel